“We firmly believe in protecting the interests of our shareholders and clients. Given recent cash flows into the small cap value discipline, we believe that closing the Fund to new investors is in their best interest and will ensure the integrity of the investment process,” states Jim Stueve, President of RidgeWorth Investments.

The Fund, with approximately $1.38 billion* in assets under management, invests primarily in U.S. companies with market capitalizations of less than $3 billion, and which the fund managers believe are undervalued in the market place at the time of purchase. The Fund’s disciplined and methodical bottom-up stock selection with an emphasis on dividends, valuation and fundamentals are cornerstone to its investment process.

About RidgeWorth Investments

RidgeWorth Investments serves as a holding company that owns interests in six investment boutiques with approximately $46.6 billion of assets under management as of December 31, 2011. RidgeWorth’s investment boutiques manage a wide variety of investment disciplines across the fixed income and equity management asset classes. Our boutiques provide investment management services to a growing client base that includes endowments, foundations, corporations, healthcare organizations, municipalities, public funds, associations, insurance companies, labor unions and high net worth individuals. In addition, RidgeWorth serves as the investment adviser to the RidgeWorth Funds mutual fund family. RidgeWorth Investments is a trade name for RidgeWorth Capital Management, Inc., an investment adviser registered with the SEC headquartered in Atlanta. For more information about RidgeWorth, visit www.ridgeworth.com .

An investor should consider the fund’s investment objectives, risks, and charges and expenses carefully before investing or sending money. This and other important information about the RidgeWorth Funds can be found in the fund’s prospectus. To obtain a prospectus, please call 1-888-784-3863 or visit www.ridgeworth.com . Please read the prospectus carefully before investing.

*As of March 28, 2012.

Equity securities (stocks) may be more volatile and carry more risk than other forms of investments, including investments in high grade fixed income securities. The net asset value per share of this Fund will fluctuate as the value of the securities in the portfolio changes. Value-based investments are subject to the risk that the broad market may not recognize their intrinsic values. Small capitalization funds typically carry additional risks since smaller companies generally have a higher risk of failure. Dividends reflect past performance and there is no guarantee they will continue to be paid. Past performance is not indicative of future results.

©2012 Ceredex Value Advisors LLC. Ceredex Value Advisors is a registered investment adviser with the SEC and a member of the RidgeWorth Capital Management, Inc. network of investment firms.

®2012 RidgeWorth Investments. RidgeWorth Investments is the trade name for RidgeWorth Capital Management, Inc., an investment advisor registered with the SEC and the adviser to the RidgeWorth Funds. RidgeWorth Funds are distributed by RidgeWorth Distributors LLC, which is not affiliated with the adviser.

Hefner stated, “We have spent a number of years preparing for the day that we could implement our plan of recycling fiberglass. The fourth quarter of 2011 was the right time to launch because of the needs expressed by leaders of the wind energy industry, to find an alternative to placing the damaged wind blades in landfills. According to industry professionals, these massive fiberglass components will not degrade for thousands of years if left intact. We are excited about our role in mitigating this issue and generating operating revenue.”

According to AFBG Chairman Kenneth McCleave, the company has been responsible for blade extraction in Minnesota, Montana and Texas and will be expanding its operations across the country to meet the hundreds of requests for implementation of the fiberglass recycling process patented by William Amour.

McCleave stated, “Now that we have opened the door, we are being inundated with calls and emails from around the country for the company to come to the aid of manufacturers nationwide who desire to prevent fiberglass from going to landfills. Our patented process will allow us to make useful, quality products from the fiberglass stream. Revenue is expected to grow dramatically as we expand to meet these needs.”

American Fiber Green Products, Inc. trades under the symbol AFBG. The company maintains a website at www.americanfibergreenproducts.com.

AFBG has a Strategic Partner in American Commerce Solutions, Inc. trades Over the Counter under the symbol, AACS. The Company maintains a website at www.aacssymbol.com

Under the Safe Harbor rules consider the following: Any portion of this presentation that is not historical in nature is subject to change due to any number of factors that are not under the control of the Company or its officers. As such, anyone reading this information release should consider the possibility that material differences from the information presented may occur and should be verified before any consideration to invest.

Contact: Daniel L. Hefner 813-244-9843

Source: American Fiber Green Products, Inc.

The European Union and Japan are expected to support the US in its case.

Beijing has set quotas for rare earth exports, many of which are critical to the manufacture of high-tech products.

The US argues that by limiting exports China, the world’s largest rare earth producer, has pushed up prices.

China produces more than 95% of the world’s rare earth metals, and any restriction on exports from Beijing is likely to have a bearing on global prices.

There have also been concerns that Beijing has implemented these quotas in a bid to ensure that prices of these elements remain low within China, a move that critics say gives its manufacturers an unfair advantage.

However, China has denied these allegations, saying that it had enforced these quotas to ensure there was no environmental damage caused due to excessive mining.

One can’t help but wonder if this isn’t a case of the United States shooting itself in the foot, so to speak, by killing rare earth production years ago.

While there was the obvious play during last year’s news hype and associated price movement, I don’t see long-term viability here, as there are numerous other countries with rare earth reserves and the unfortunate willingness to exchange environmental purity for dollars, euros or yen if the price is right.

That said, where do you think the rare earth situation is headed?  Are you getting involved or simply watching from the sidelines, and what companies (if any) do you like?

Fourth Quarter Highlights

• Revenue increased $32.9 million or 7.3% compared to prior year;
• Gross profit was $81.8 million or 16.9% of revenue, compared to $72.6 million or 16.1% of revenue in the prior year;
• Adjusted EBITDA generated by the segments before allocation of corporate expenses was $27.2 million, compared to $21.4 million last year;
• Adjusted EBITDA was $19.8 million, compared to $10.0 million in the prior year;
• Net income was $6.7 million or $0.12 per diluted share, compared to prior year net loss of $67.1 million or $1.25 per share.

“We are pleased with our fourth quarter results driven by solid organic growth and significant momentum in our key businesses. Infusion revenue was strong on both a sequential and year-over-year basis driven by the depth of our managed care contracts, growing patient census, and the focused and productive efforts of our sales team and regional management who continue to focus on our targeted therapies,” said Rick Smith, President and Chief Executive Officer of BioScrip.

“With the pending sale of our community specialty pharmacies and centralized specialty and mail service pharmacy businesses, we are positioning BioScrip as a leaner company focused on those areas where we have key strengths, in-market awareness and offer distinct competitive advantages. This includes leveraging our geographic reach, building upon our reputation for clinical excellence, deepening our relationships with national and local managed care customers and strategically expanding our national infusion service footprint both organically and through tuck-in acquisitions. As we move through 2012, we will continue to take action to further rationalize corporate overhead, improve operating performance and profitability, and maximize overall operating cash flow generation,” concluded Smith.

Results of Operations
Fourth Quarter 2011 versus Fourth Quarter 2010

Revenue for the fourth quarter of 2011 totaled $483.3 million, compared to $450.4 million for the same period a year ago, an increase of $32.9 million or 7.3%. Infusion/Home Health Services revenue for the fourth quarter of 2011 was $121.6 million compared to $112.6 million in the prior year, an increase of $9.1 million or 8.0%. Pharmacy Services revenue for the fourth quarter of 2011 was $361.7 million, compared to $337.8 million for the prior year period, an increase of $23.9 million or 7.1%.

Consolidated gross profit for the fourth quarter of 2011 was $81.8 million, or 16.9% of revenue, compared to $72.6 million, or 16.1% of revenue, for the fourth quarter of 2010.

Fourth quarter 2011 operating income was $14.6 million, compared to an operating loss of $3.6 million for the fourth quarter of 2010.

During the fourth quarter of 2011, BioScrip generated $27.2 million of segment Adjusted EBITDA, or 5.6% of total revenue, compared to $21.4 million, or 4.7% of total revenue in the prior year. The Infusion/Home Health segment generated $12.3 million of Adjusted EBITDA, or 10.1% of segment revenue. This compares to $11.8 million, or 10.4% of segment revenue in the prior year. The Pharmacy Services segment generated $14.9 million of segment Adjusted EBITDA, or 4.1% of segment revenue. This compares to $9.6 million, or 2.8% of segment revenue in the prior year.

On a consolidated basis, BioScrip reported $19.8 million of Adjusted EBITDA during the fourth quarter of 2011, or 4.1% of total revenue, compared to $10.0 million, or 2.2% of total revenue, in the prior year.

Interest expense in the fourth quarter of 2011 was $6.8 million, compared to $8.1 million in the prior year.

Net income for the fourth quarter of 2011 was $6.7 million, or $0.12 per share, compared to a net loss of $67.1 million, or $1.25 per share, in the prior year.

Full Year 2011 versus Full Year 2010

Revenue for the year ended December 31, 2011, was $1.8 billion compared to $1.6 billion for the comparable prior year period. Infusion/Home Health Services segment revenue for the year ended December 31, 2011, was $451.0 million, compared to $377.2 million for the prior year, an increase of $73.8 million, or 19.6%. This increase was largely a result of incremental revenue from the Critical Homecare Solutions, Inc. (“CHS”) business, which was acquired March 25, 2010. Excluding the incremental first quarter revenue associated with the acquired CHS business, BioScrip’s Infusion/Home Health Services segment revenue increased $10.5 million, or 2.8% over the prior year as a result of overall volume growth.

Pharmacy Services segment revenue for the year ended December 31, 2011, was $1.4 billion compared to revenue of $1.3 billion for the prior year period, an increase of $105.6 million, or 8.4%. Pharmacy Services revenue increased due to volume from new managed care contracts, growth in the oncology, rheumatoid arthritis and multiple sclerosis therapies, industry-wide drug inflation and an increase in discount cash card programs sales.

Consolidated gross profit for the year ended December 31, 2011, was $312.3 million compared to $260.4 million for the same period a year ago, an increase of $51.9 million, or 19.9%. Consolidated gross profit as a percentage of revenue for the year ended December 31, 2011 increased to 17.2%, compared to 15.9% for the same period in 2010. The increase in gross profit and in gross profit as a percentage from 2010 to 2011 was primarily the result of the acquisition of CHS, which favorably impacted gross margin rates, and growth in discount cash card program volumes.

For the year ended December 31, 2011, BioScrip generated $103.4 million of segment Adjusted EBITDA, or 5.7% of total revenue, compared to $84.2 million, or 5.1% of total revenue, for the prior year period. The Infusion/Home Health segment generated $45.4 million of segment Adjusted EBITDA, or 10.1% of segment revenue, compared to $43.5 million, or 11.5% of segment revenue, in the prior year. The Pharmacy Services segment generated $58.0 million of segment Adjusted EBITDA, or 4.2% of segment revenue, compared to $40.7 million, or 3.2% of segment revenue, in the prior period.

On a consolidated basis, BioScrip reported $73.5 million of Adjusted EBITDA for the year ended December 31, 2011, or 4.0% of total revenue, compared to $49.2 million, or 3.0% of total revenue, in the prior year.

Interest expense for the year ended December 31, 2011, was $28.3 million, compared to $27.6 million for the same period in 2010. The increase in interest expense was related to a full year of interest on the debt instruments primarily used to finance the CHS acquisition.

Income tax expense for the year ended December 31, 2011, was $1.3 million on a pre-tax net income of $9.2 million and consisted primarily of state income taxes and a deferred tax provision associated with tax deductible goodwill. Our income tax expense was $47.7 million for the year ended December 31, 2010, on a pre-tax net loss of $21.4 million. Income tax expense in 2010 includes the establishment of a $54.0 million valuation allowance recorded against deferred tax assets.

Net income for the year ended December 31, 2011, was $7.9 million, or $0.14 per share. This compares to a net loss of $69.1 million, or $1.37 per share for the same period in 2010.

Liquidity and Capital Resources

For the year ended December 31, 2011, BioScrip generated $27.0 million in net cash from operating activities compared to $21.4 million used in operating activities during the year ended December 31, 2010, an increase of $48.4 million. This was due to a decrease in working capital requirements of $23.1 million and an increase of $25.3 million in net income adjusted for non-cash items, primarily such as depreciation and amortization, deferred income taxes and in 2010 the loss on early extinguishment of debt.

Conference Call

BioScrip will host a conference call to discuss its fourth quarter 2011 financial results on March 9, 2012 at 8:30 a.m. Eastern Time. Interested parties may participate in the conference call by dialing 800-707-7427 (US), or 303-223-2680 (International), 5-10 minutes prior to the start of the call. A replay of the conference call will be available for two weeks after the call’s completion by dialing 800-633-8284 (US) or 402-977-9140 (International) and entering conference call ID number 21579469. An audio webcast and archive will also be available under the “Investor Relations” section of the BioScrip website at www.bioscrip.com .

About BioScrip, Inc.

BioScrip, Inc. ( www.bioscrip.com ) BIOS +3.17% is a national provider of specialty pharmacy and home health services that partners with patients, physicians, hospitals, healthcare payors and pharmaceutical manufacturers to provide clinical management solutions and delivery of cost-effective access to prescription medications and home health services. Our services are designed to improve clinical outcomes with chronic and acute healthcare conditions while controlling overall healthcare costs.

Forward Looking Statements — Safe Harbor

This press release may contain statements which constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the intent, belief or current expectations of the Company, its directors, or its officers with respect to the future operating performance of the Company, Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. Important factors that could cause such differences are described in the Company’s periodic filings with the Securities and Exchange Commission.

Reconciliation to Non-GAAP Financial Measures

EBITDA or earnings before interest, taxes, depreciation and amortization (“EBITDA”) and Adjusted EBITDA, which excludes loss on extinguishment of debt, stock-based compensation expense, acquisition, integration, severance and other employee costs, bad debt relating to CAP contract termination and legal settlement costs, are non-GAAP financial measures as defined under U.S. Securities and Exchange Commission Regulation G. As required by Regulation G, BioScrip has provided on Schedule 4 a reconciliation of this measure to the most comparable GAAP financial measure. The non-GAAP measure presented provides important insight into the ongoing operations and a meaningful benchmark to evidence the Company’s continuing profitability trend.

What Happened?

Save the World Air is coming into its own at the right time; which is essential to success. ZERO’s patented technology allows oil and gas pipeline operators to temporarily reduce the viscosity of the crude oil within their pipeline(s) to reduce the fluid-drag (also known as friction-loss) between the fluid and the pipeline.

By reducing the friction loss, pipeline operators’ pump systems require less energy to maintain a constant flow rate, thereby directly reducing daily operation costs. The Company’s intellectual property portfolio includes 24 domestic and international patents and patents pending, which have been developed in conjunction with and exclusively licensed from Temple University.

The Company’s ELEKTRA technology improves diesel engine efficiency for industrial diesel engines, as well as diesel-powered trucks, trains, marine vessels, military fleets and jet turbines.

But Back to Pipelines…

In late Feb Save the World Air signed a new five-year operating agreement with the United States Department of Energy’s Rocky Mountain Oilfield Testing Center. This five-year agreement extends through the end of 2016.

In 2011, together with the United Stated Department of Energy’s Rocky Mountain Oilfield Testing Center, ZERO designed and retrofitted a purpose-built 4.5 mile underground oil pipeline testing facility in order to test the Company’s Applied Oil Technology (AOT) under simulated real-world conditions. The Company’s AOT technology yielded pipeline operational efficiency improvements of over 13%.

The purpose of the new operating agreement is to continue field testing to confirm the Company’s technology’s effectiveness in improving oil pipeline operational efficiencies. “By continuing our collaboration with the United States Department of Energy and field testing our technologies at the Rocky Mountain Oilfield Testing Center, we validate the effectiveness of our technology for the key decision makers in both industry and government,” stated ZERO Chairman and CEO, Cecil Bond Kyte.

Today the Company announced it had signed a Letter of Intent with LG Partners, LLC, to incorporate ZERO’s AOT oil pipeline efficiency technology into the design and construction of a proposed new non-domestic, multi-national, 900-mile pipeline currently in the planning stage.

LG Partners is currently developing the $2.5 billion, 900-mile pipeline to transport medium and heavy crude oil to markets currently experiencing a lack of diverse pipeline suppliers. This multinational pipeline is designed to be 42″ in diameter, with a transport capacity of 30 to 60 million tons of crude oil per year, or approximately 600,000 to 1.2 million barrels per day.

Improved flow efficiency above 13% certainly has its fans when it comes to saving millions in operating costs. Apparently the folks at ZERO are doing everything right. Good for long-term shareholders who’ve benefitted from management’s hard work.